Pharmacotherapy Oral Hypoglycemic Agents (OHA) Antihyperglycemic agents Used only in type 2 diabetes, with diet and exercise CDA Clinical Practice Guidelines.

Slides:



Advertisements
Similar presentations
Oral Hypoglycemic Drugs And Classifications
Advertisements

Agents Used in the Treatment of Hyperlipidemia
Canadian Diabetes Association Clinical Practice Guidelines Weight Management in Diabetes Chapter 17 Sean Wharton, Arya M. Sharma, David C.W. Lau.
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach Update to a Position Statement of the American Diabetes Association.
Canadian Diabetes Association Clinical Practice Guidelines Pharmacologic Management of Type 2 Diabetes Chapter 13 William Harper, Maureen Clement, Ronald.
Diabetes (abridged!). Who needs screening for DM? Age >45 Obese – BMI >25 1 st degree relative with DM Racial groups: –African American –Hispanic American.
Farxiga™ - Dapagliflozin
Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins Introduction to Clinical Pharmacology Chapter 42- Antidiabetic Drugs.
Glycogen Metabolism Storage and Mobilization of Glucose NUTR 543 – Advanced Nutritional Biochemistry David L. Gee, PhD Professor of Food Science and Nutrition.
Oral Medications to Treat Type 2 Diabetes
Combination Therapy in Type 2 Diabetes
Clinical Protocol Using Insulin Pump Easy Guideline for Initiating Insulin Pumps on Type 2 Diabetes Patients.
Perioperative Diabetes Management Dr. Ken Locke March 2007.
LONG TERM BENEFITS OF ORAL AGENTS
Afrezza® – inhaled human insulin
Drugs used in Diabetes Dr Sally Hudson. BIGUANIDES reduce output of glucose from the liver and enhances uptake and use of glucose by muscle cells ExampleADVANTAGESDISADVANTAGESCOSTCaution.
Treatment of diabetes:  Life style modification  Insulin  Oral hypoglycemic agents.
PRE-EXISTING DIABETES AND PREGNANCY 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.
Criteria for the diagnosis of DM Symptoms of diabetes plus random blood glucose concentration ≥ 200 mg/dl OR FPG ≥ 126 mg/dl OR Two –hour plasma glucose.
oral hypoglycemic agents
Oral Hypoglycemic Drugs
Oral hypoglycemic drugs Prof. Mohammad Alhumayyd.
Oral hypoglycemic drugs Prof. Mohammad Alhumayyd.
TYPE 2 DIABETES MELLITUS REVIEW OF Clinical Practice Guidelines WEEK 2: Therapy UHN AIMGP CLINIC SEMINAR SERIES 2007 Updates Dr. K. Tzanetos WEEK 2: Therapy.
Diabetes Mellitus - Mgt Calculate and define diets for diabetes mellitus. Integrate physiological functions of organ systems and effects of disease on.
Oral hypoglycemic drugs
1 Core Defects of Type 2 Diabetes Targeting Mechanisms for a Comprehensive Approach 1 Part 3 of 4.
Basal Bolus: The Strategy for Managing All Diabetes Fall, 2003 Paul Davidson, MD, FACE Atlanta Diabetes Associates Atlanta, Georgia.
DIABETES IN THE ELDERLY 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.
Clinical Practice Glycemic Management of Type 2 Diabetes Mellitus Faramarz Ismail-Beigi, M.D., Ph.D. Dr.kalantar N Engl J Med Volume 366(14):
The Role of DPP-IV Inhibitors in the Management of Type 2 Diabetes
Pramlintide Therapy Part 2 of 2 Pharmacodynamic Review Type 1 Diabetes Efficacy Safety.
Identify the risk factors, diagnosis and prevalence of diabetes in the United States. Describe the function of the pancreas, the intestines and liver.
DH206: Pharmacology Chapter 21: Diabetes Mellitus Lisa Mayo, RDH, BSDH.
Oral hypoglycemic drugs
SGLT-2 Inhibitors Surprising New Information. Logic for SGLT-2 Inhibition : My Own Comment on MOA- Logic for Benefit: 1.Kidney is an ‘active player’ in.
Oral Diabetes Medications Carol Cordy, MD. Goals Understand how type 2 diabetes affects many organs and how this changes over the course of the illness.
DIET CONTROL  All diabetic patients should be on diet control.  Diet control is a must either the patient is taking insulin or oral therapy.  Over.
1 ‘Medicines used in the management of Type 2 Diabetes’ Dr Susan McGeoch, Specialist Registrar in Diabetes Sandra Wilson, Diabetes Specialist Nurse.
Dr. Mansour Alzahrani. متى اكتشف داء السكري؟ داء السكري في الحضارة الهندية والصينية القديمة اسهامات علماء المسلمين في داء السكري.
Management of Obesity in Diabetes Key Messages An estimated 80 to 90% of persons with type 2 diabetes are overweight or obese. A modest weight loss of.
Introduction Subcutaneous insulin absorption is not reproducible and insulin entry directly into the circulation is not linked to glucose sensing Basal.
Dr. Sasan Zaeri (PharmD, PhD) Department of Pharmacology, BPUMS.
A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Clerk 陳威任.
Fig. 2. Change in (A) glycosylated hemoglobin (HbA1c) and (B) fasting plasma glucose (FPG). Group A: oral hypoglycemic agents (OHAs; sulfonylurea+metformin.
Fig. 1. Study flow chart. Group A: intensifying oral hypoglycemic agents (OHAs; sulfonylurea+metformin dose titration or fixed-dose combination added to.
Diabetes in the Pediatric Population
2012 ADA Clinical Practice Guidelines Therapies for DM- Type 2
Dr. Sasan Zaeri (PharmD, PhD) Department of Pharmacology, BPUMS
Lecture on Anti Diabetic Drugs
Recommendation In people with clinical cardiovascular disease in whom glycemic targets are not met, a SGLT2 inhibitor with demonstrated cardiovascular.
LONG TERM BENEFITS OF ORAL AGENTS
Oral hypoglycemic drugs
Drugs for Diabetes Mellitus
Program Goals. Inhaled Insulin: Overcoming Past Obstacles With Advances in Understanding.
oral hypoglycemic agents
What Do Primary Care Physicians Need to Know About Insulin/GLP-1 RA Fixed-Ratio Combinations?
GLP-1 Receptor Agonists: How Early Is Appropriate?
Metabolic Syndrome (N=160) Non-Metabolic Syndrome (N=138) 107/53
Integrated Diabetes Care: How Can We Make the Best Use of New Technology?
Introduction to Clinical Pharmacology Chapter 42- Antidiabetic Drugs
Dual SGLT1/SGLT2 Inhibition in T1D
Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.
Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.
INSULINS Dr.R.Sajjad december INSULINS Dr.R.Sajjad december 2018.
ATL-801 treatment increases insulin sensitivity in KKAY mice.
Fixed-Ratio Combination Therapy in T2DM
Fig. 1. Antihyperglycemic therapy algorithm for adult patients with type 2 diabetes mellitus (T2DM). The algorithm stratifies the choice of medications.
Fresh perspectives ON BASAL Insulins in diabetes care
Presentation transcript:

Pharmacotherapy Oral Hypoglycemic Agents (OHA) Antihyperglycemic agents Used only in type 2 diabetes, with diet and exercise CDA Clinical Practice Guidelines “Pharmacologic Management of Type 2 Diabetes, p S53

GenericBrandAdvantagesDisadvantagesA1C ↓ MetforminGlucophage, Glumetza -Weight neutral -low risk of hypoglycemia -GI side effects (nausea, bloating, diarrhea, decreased appetite) 1-2% Mechanism of Action: ↓ hepatic glucose production and intestinal glucose absorption, ↑glucose uptake and insulin sensitivity, lowers basal and post-prandial blood glucose levels Comments: -first line agent in type 2 -good as initial therapy especially if overweight -best to gradually increase dose to ↓ GI side effects -Contraindicated if CrCl/eGFR <30 mL/min or hepatic failure -Caution with renal insufficiency (eGFR<30ml/min) -lactic acidosis may be precipitated by renal impairment, excessive alcohol intake, hepatic disease, acute CHF Pharmacotherapy Class: Biguanides (Insulin Sensitizer)

GenericBrandAdvantagesDisadvantagesA1C ↓ Glyburide* Gliclazide Glimepiride Repaglinide Diabeta Diamicron Amaryl Gluconorm -rapid effect-weight gain, risk of hypoglycemia, dizziness, headache, nausea, weakness -expensive 1-2% Mechanism of Action: Stimulates functional β cells in pancreas to release insulin, ↓ glucose output from liver Comments: -take with food -hypoglycemia and weight gain are especially common with glyburide* -caution with patients at high risk of hypoglycemia (e.g. the elderly, renal/hepatic failure) Pharmacotherapy Class: Sulfonylureas and Meglitinides (Insulin Secretagogues)

GenericBrandAdvantagesDisadvantagesA1C ↓ AcarboseGlucobay Prandase -Weight neutral -low risk of hypoglycemia -GI side effects (diarrhea, gas, cramps, liver dysfunction) % Mechanism of Action: Delays digestion of CHO and gastrointestinal absorbtion of glucose. Inhibits pancreatic amylase and membrane bound intestinal α-glucoside hydrolase. Comments: -Take with food (first bite of meal) -Takes up to 8 weeks for maximum efffect -Not recommended as initial therapy in people with marked hyperglycemia (A1C >9.0%) Pharmacotherapy Class: Alpha-glucosidase inhibitors

GenericBrandAdvantagesDisadvantagesA1C ↓ Pioglitazone Rosiglitazone Actos Avandia -improved lipid profile, low risk of hypoglycemia, potential decrease in MI (pio) -Slow onset, fluid retention, weight gain, bone fractures, expensive, potential increase in MI (rosi) 0.5-2% Mechanism of Action: ↓ insulin resistance, improves target cell response to insulin, ↓ hepatic glucose production Comments: -may induce ovulation -only covered by blue cross through special authorization –must be intolerant to metformin -take at same time everyday -some blood pressure lowering Pharmacotherapy Class: Tiazolidinidediones (TZD) or Glitazones (Insulin sensitizers)

GenericBrandAdvantagesDisadvantagesA1C ↓ Liraglutide Exenatide Victoza Byetta -weight loss, low risk of hypoglycemia -injection, expensive, long-term safety not established, GI side effects % Mechanism of Action: Glucagon Like Peptide 1 (GLP-1) receptor agonists act to ↑ insulin release in the presence of ↑ glucose, ↓ glucagon secretion and delay gastric emptying Comments: -may be beneficial for weight loss -may delay gastric emptying and impact absorption of oral meds (caution with antibiotics and contraceptives) -caution with patients at high risk of hypoglycemia (e.g. the elderly, renal/hepatic failure) Pharmacotherapy Class: Glucacon Like Peptide 1 (GLP-1) (Incretins)

GenericBrandAdvantagesDisadvantagesA1C ↓ Sitagliptin Saxagliptin Januvia Onglyza -weight neutral, low risk of hypoglycemia -expensive, long- term safety not established % Mechanism of Action: DPP-4 is an enzyme that breaks down the incretin hormones GIP and GLP-1 to help increase the release of insulin and decrease glucagon levels in the circulation Comments: -Better post prandial glucose control Pharmacotherapy Class: Dipeptidylpeptidase 4 (DPP-4) Inhibitors (Incretin)

Pharmacotherapy Insulin Rapid Acting – Humalog (lispro) Short Acting – Humulin R – Novolin Intermediate Acting – Humulin N Long Acting – Lantus – Levemir